New eBook: Flexible Infrastructure for Smarter Scale in Advanced Therapies
Advanced therapy developers are being asked to do more with less. Programs need to move faster, reach more patients, support more geographies, and stay ready for evolving regulatory expectations, all while capital remains tightly managed.
That creates a difficult question for cell and gene therapy teams: how do you build the infrastructure needed to scale without tying up too much capital too early?
Cryoport Systems’ new eBook, Flexible Infrastructure: Minimizing CapEx for Smarter Scale in Advanced Therapies, explores that question across the advanced therapy lifecycle. The eBook looks at how developers can preserve capital, reduce operational risk, and avoid overbuilding fixed infrastructure before their programs are ready to use it.
For many organizations, infrastructure planning starts with good intentions. But for advanced therapies, the path from pre-clinical development to commercialization rarely moves in a straight line. Timelines shift and enrollment changes, or manufacturing strategies evolve. Maybe new markets open sooner, while others take longer to materialize.
When too much capital is tied up in owned infrastructure, those investments can become rigid and make it difficult to adapt. The eBook makes the case for a more flexible approach, where instead of building a large physical footprint early, developers can focus on building a strong supply chain foundation. This approach is especially important as therapies progress from early development into clinical trials and commercialization. What works for a small number of patients and sites can become more challenging as volumes increase, geographies expand, and more stakeholders become involved. Fragmented vendor networks can add complexity at exactly the point when teams need consistency.
An integrated, end-to-end supply chain model can help reduce that burden. By connecting capabilities such as cryopreservation, biostorage, kitting, secondary packaging and labeling, temperature-controlled logistics, and regulatory support within a single framework, developers can scale with greater confidence and fewer handoffs.
For advanced therapy developers, scale is about staying adaptable while protecting product integrity as much as it’s about adding capacity. Explore how a more elastic supply chain strategy can support growth from early development through global commercialization.
